93 results about "Cellular composition" patented technology

The invention belongs to the technical field of tumor micro-immune environments, and particularly relates to a kit for detecting a tumor micro-environment, a detection method and application, the kit comprises rare metal element labeled monoclonal antibodies, the rare metal element labeled monoclonal antibodies comprise 115In-CD20, 139La-Histone H3, 142Nd-CD56, 144Nd-CD14, 146Nd-Vimentin, 148Nd-Pan-CK, 151Eu-CD31, 156Gd-CD4, 158Gd-E-Cadrin, 159Tb-CD68, 162Dy-CD8a, 166Er-CD45, 167Er-CD15, 170Er-CD3, 171Yb-CD11c and 209Bi-alpha-SMA, and the rare metal element labeled monoclonal antibodies comprise The invention can be used for simultaneously detecting and researching the quantity, positioning and spatial topological relation of each cell component in a tumor microenvironment, and provides a multi-immunofluorescence detection kit and method for ubiquitous epithelial differentiation-derived tumors based on an imaging mass spectrum flow technique. A plurality of biomarkers can be analyzed at the same time by using multiple immunohistochemical staining and rare earth metal tag signal detection technologies, so that the aim of performing high-dimensional analysis on a tumor microenvironment is fulfilled according to cell composition, functional state and cell-cell space interaction relationship.

The invention relates to a method for determining at least part of the cellular composition of at least one biological sample comprising leukocytes, wherein the proportion of at least one type of leukocyte is determined based on the identified methylation levels, in order to predict the relative distribution of that type of leukocyte in the sample. The invention further relates to the use of at least one artificial nucleic acid molecule for determining at least part of the cellular composition of a biological sample comprising leukocytes according to the above-mentioned method. In the context of the invention, the following CpG sites according to the invention with cell-type-specific methylation could be identified: cg22381196 (DHODH), cg12483340 (TMEM87A), cg06270401 (DYRK4), cg23054181 (FAM169BP), cg26076724 (RP11-146I2.2), cg12249234 (KSR1), cg04468741 (MICAL2), cg05074138 (CTLA4), cg05705140 (LINC01237), cg15564619 (SKI), cg11531557 (HMBOX1), cg02212339 (TRPV1), cg22488278 (ZFYVE28), cg02240030 (MAD1L1) and cg24408769 (JARID2).

The present disclosure relates to cellular compositions that are modified to introduce a nucleic acid or vector expressing the same. Such compositions may be used to deliver nucleic acid to a target cell and treat disease such as cancer.

A method of imaging a cellular composition is disclosed. The method comprises the steps of contacting the cellular composition with a luminescent compound and imaging the cellular composition with a time-resolved spectroscopic technique. The luminescent compound exhibits a first luminescent state having a first emission lifetime in a first chemical environment and a second luminescent state having a second, different, emission lifetime in a second chemical environment. Also disclosed are luminescent compounds, compositions comprising an amphiphilic polymer and a luminescent compound, and the use of a luminescent compound in combination with a time-resolved spectroscopic technique for imaging a cellular composition.

The invention belongs to the technical field of cell bionic nano-drugs, and particularly discloses a cell bionic nano-particle as well as a construction method and application thereof. And performing simple ultrasonic fusion on the target cell membrane and the hydrophobic nano-core to obtain the cell bionic nano-particles. The bionic nano-cell can effectively inherit and simulate functional protein on the surface of a source cell membrane, systematically replace functions of the source cell in physiological and pathological processes, such as inflammatory factor adsorption, migration factor adsorption and the like, interfere and inhibit the disease process from the cellular mechanism, regulate and control cell composition and immune microenvironment of a focus part, and improve the immune function of the source cell membrane. The medicine does not need to be additionally carried. Aiming at the related pathogenesis of immune tolerance deficiency, the invention innovatively provides a therapeutic strategy for constructing immune tolerance. The homology and inherent immunosuppressive ability of tumor cells to the focus part of the autoimmune disease are reversely used, immune tolerance of the focus part based on immune checkpoints is reconstructed, meanwhile, target cells are replaced to adsorb autoimmune antibodies, and the immune response level is reduced.

The invention provides improved anti-BCMA CAR T cell compositions for adoptive T cell therapy for relapsed / refractory multiple myeloma.

Methods and systems for analysing the cellular composition of a sample are described, comprising: providing an image of the sample in which a plurality of cellular populations are associated with respective signals and classifying a plurality of query cells in the image between a plurality of classes corresponding to respective cellular populations in the plurality of cellular populations. This is performed by providing a query single cell image to an encoder module of a machine learning model to produce a feature vector for the query image, and assigning the query cell to one of the plurality of classes based on the feature vector for the query image and feature vectors produced by the encoder module for each of a plurality of reference single cell images. The machine leaning model comprises: the encoder module, configured to take as input a single cell image and to produce as output a feature vector the single cell image, and a similarity module configured to take as input a pair of feature vectors for a pair of single cell images and to produce as output a score indicative of the similarity between the single cell images. Thus, the machine learning model can be obtained without the need for an extensively annotated dataset. The methods find use in the analysis of multiplex immunohistochemistry / immunofluorescence in a variety of clinical contexts.

Provided herein are methods for multiplexed in situ analysis of biomolecules in a tissue. In particular, provided herein are methods for multiplexed single-cell in situ protein and nucleic acid profiling in fixed or fresh tissues, that allows the investigation of the different cell compositions and their spatial organizations in intact tissues through consecutive cycles of probe hybridization, fluorescence imaging, and signal removal.

The invention provides improved anti-BCMA CAR T cell compositions for adoptive T cell therapy for relapsed / refractory multiple myeloma.

The present disclosure relates to improved cell intermediates and potency assays for obtaining the improved cell intermediates. Such intermediates and assays can be suitable for providing cellular compositions for the treatment of various inflammatory conditions.

The present application relates to apparatus and methods for cellular composition. Embodiments of the invention provide systems, methods and apparatus for real-time cellular composition / generation of music using cells (i.e. short musical motifs), wherein the cellular composition relies on user data.

To provide a system and a method for deconvolution of expression data.SOLUTION: A method for determining one or more cell composition percentages from expression data includes obtaining expression data for a biological sample. The biological sample has previously been obtained from a subject, and the expression data includes first expression data associated with a first set of genes associated with a first cell type. The method also includes determining a first cell composition percentage for the first cell type using the expression data and one or more non-linear regression models including a first non-linear regression model. The first cell composition percentage indicates an estimated percentage of cells of the first cell type in the biological sample, and in the determining step, the first cell composition percentage for the first cell type is determined by processing the first expression data with the first non-linear regression model. The method further includes outputting the first cell composition percentage.SELECTED DRAWING: Figure 2A

The invention provides a spatial transcriptome cell composition inference method based on graph contrast learning. According to the method, a cross-modal low-dimensional feature spatial data simulation module is constructed, single cell and spatial transcriptome data are respectively mapped to a potential embedding space, feature space difference is reduced through aligned distribution, and structural consistency of cross-modal data is enhanced; designing a double heterogeneous graph construction and potential relation learning module, constructing a feature heterogeneous graph of two cells and spatial points based on gene expression similarity, and capturing a high-level potential relation of spatial data in double graphs by adopting a meta-path potential relation reasoning strategy; and introducing a graph representation optimization mechanism based on structure contrast learning, maximizing the consistency of the cross-modal nodes in the embedding space, and obtaining a final cell composition inference result. The method realizes inference of spatial transcriptome data cell composition, can be used for cell space positioning and tissue microenvironment analysis, and provides a reliable computational analysis basis for related biomedical research.

The invention discloses a construction method and application of a cerebellar organoid model, and belongs to the technical field of organoid culture. According to the method, the stability and repeatability of cerebellar organs are remarkably improved by optimizing the components of the culture medium and the induction process. Key morphogenetic factors are regulated and controlled in a stepped mode, and cells are accurately guided to be directionally differentiated to cerebellum; meanwhile, a culture medium without Matrigel is used in the nerve expansion and maturation stages, batch variation of exogenous matrixes is eliminated, and development path consistency and cell composition uniformity are ensured. The organoid constructed on the basis of the method has remarkable advantages in SCA3 disease modeling, single cell sequencing proves that the difference in batches is remarkably smaller than that of an existing method, and a reliable in-vitro human model platform is provided for SCA3 mechanism research and drug screening.

There is provided an anti-GD2 CAR T cell composition, a method for making such a composition and its use in the treatment of diseases such as Neuroblastoma.

Compositions comprising a population of oligodendrocyte progenitor cells (OPCs), as well as methods of making and using the same, are provided. In one aspect, a container comprising a composition, where the composition comprises a population of cells comprising a plurality of OPCs, and where the population of cells comprises less than 15% undesirable cell types is provided. In another aspect, the population of cells comprises less than 15% undesirable epithelial lineage cells. In yet another aspect, the population of cells comprises less than 2% K7 positive cells. In an aspect, a population of cells comprising a plurality of oligodendrocyte progenitor cells is capable of forming less than one epithelial cyst per 100,000 cells in a cyst assay is provided. An even further aspect of the present disclosure is a container comprising a composition, where the composition comprising a plurality of oligodendrocyte progenitor cells is useful in treating treat stroke, spinal cord injury, and multiple sclerosis.

Continuous counter-flow centrifugation methods for producing cell compositions, including those for the production of T cell therapeutics, including cells expressing recombinant receptors such as chimeric antigen receptors (CARs), are provided.

Disclosed are chimeric stimulatory receptors (CSRs), cellular compositions comprising the CSRs, methods of making the same, and methods of using the same for treating a disease or condition in a subject.

The present invention provides, in some embodiments, isolated cell compositions suitable for adoptive immunotherapy, methods for making the cell compositions, and therapeutic methods using the cell compositions. The compositions comprise at least about 10 mAbs specific for a target peptide antigen in a pharmaceutically acceptable carrier. 6 The compositions comprise CD8+ T cells and include T memory stem (TSCM) cells. In various embodiments, the compositions are about 1% to about 100% T memory stem cells, providing robust and durable adoptive therapy and providing advances in T cell engineering.

Provided herein are methods for multiplexed in situ analysis of biomolecules in a tissue. In particular, provided herein are methods for multiplexed single-cell in situ protein and nucleic acid profiling in fixed or fresh tissues, and also allows the investigation of the different cell compositions and their spatial organizations in intact tissues through consecutive cycles of probe hybridization, fluorescence imaging, and signal removal.

Provided herein are methods and systems for sensitive and multiplexed in situ analysis of samples such as biological samples using cleavable fluorescent streptavidin. In particular, provided herein are methods for multiplexed single-cell in situ biomolecule profiling in samples, including fixed or fresh tissues, and also allows the investigation of the different cell compositions and their spatial organizations in intact tissues through consecutive cycles of probe hybridization, fluorescence imaging, and signal removal.

The present disclosure relates to a method of reducing urine glycosaminoglycans (GAG) or cerebral spinal fluid (CSF) glycosaminoglycans (GAG) in a subject, comprising: administering a single dose of a population of modified B cells to the subject.

The disclosure relates to a cell culture method for deriving a multipotent neuromesodermal progenitor (NMP) cell and / or lineages of specific anterior-posterior positions along the human body axis and / or cell types of matched anterior-posterior position, from a human pluripotent stem cell (PSC), comprising culturing said stem cell under conditions and with reagents modulating the following signalling pathways: (i) activation of FGF signalling for a duration of about 12-120 hours; (ii) activation of WNT signalling for a duration of about 48-120 hours; (iii) inhibition of SMAD signalling, including TGF-beta / activin-Nodal signalling and BMP signalling, for a duration of about 48-120 hours, wherein said progenitor co-expresses SOX2, TBXT, CDX2 and CDX1 at RNA and / or protein level(s).The disclosure further relates to a composition for use in deriving multipotent NMPs and / or daughter lineages of a specific anterior-posterior position in the human body and / or cell types of matched anterior-posterior position from human pluripotent stem cells (PSC), a multipotent NMP, a cervical and a thoracic NMP obtained by culturing human PSCs, a composition for use in generating lumbar level NMPs from the multipotent NMPs, a lumbar level NMP obtained by culturing the multipotent NMP, a composition for use in generating tbx6 expressing presomitic mesoderm cells from the multipotent NMPs, a tbx6 expressing presomitic mesoderm cell obtained by culturing the multipotent NMP, a human cell derived from the multipotent NMP, a cell population, a kit and a cellular composition.

The present invention related to a compound for use in prevention or treatment of a neurodegenerative disease associated with the formation of stress granules. The compound is selected from lipoic acid, lipoamide, dihydrolipoic acid, and dihydrolipoamide. The invention further relates to a method of identifying a compound that modulates a characteristic associated with one or more condensates comprising a condensate-associated molecule, comprising: (a) contacting the compound with a cellular composition comprising one or more condensates or a cellular composition capable of forming one or more condensates, and (b) determining the characteristic associated with the one or more condensates. A modulation in the characteristic, as compared to a reference, indicates that the compound modulates the characteristic associated with the one or more condensates.

The invention relates to a cell composition and a cell dressing for repairing skin injury and regenerating hair follicles and application of the cell composition and the cell dressing, active cells of the cell composition comprise hair papilla cells, keratinocytes and fibroblasts, and the number ratio of the hair papilla cells to the keratinocytes to the fibroblasts is (1-3): (1-3): (1-3). The cell material provided by the invention can treat or repair skin injury, especially head skin injury, and can promote hair regeneration while repairing the skin injury.

This invention relates to an in vitro method for mapping the spatiotemporal electrophysiological dynamics and spatial transcriptional profiles of cells in a functional neuronal cell ensemble. This in vitro method includes simultaneously recording and analyzing spatial data of molecular activity and electrical network activity at the level down to individual cells using high-density electrobiosensors, spatial transcriptomics, optical imaging, and advanced computational strategies. The invention also relates to: methods for identifying the composition of a functional neuronal ensemble; methods for monitoring the spatiotemporal electrophysiological dynamics and transcriptional profiles of cells in a functional neuronal cell ensemble; methods for monitoring the cellular composition of a functional neuronal ensemble; methods for identifying compounds that influence spatial electrophysiological and transcriptional dynamics; and / or methods for identifying the cellular composition of a functional neuronal cell ensemble based on detected dynamics; and devices thereof. This invention allows for a better understanding of disease mechanisms, the identification of therapeutic targets, and the development of new drugs and treatment regimens.

Provided herein, in some embodiments, are methods and compositions (e.g., cell compositions) for the treatment of cancer.

Provided herein are methods of hypoimmunogenicity, such as bioengineering methodologies and materials, including hypoimmunogenicity (such as engineering hypoimmunogenicity) methodologies and materials useful in, for example, genetically modifying and / or otherwise altering at least one target gene or gene product, processes for producing engineered hypoimmunogenic cells, manufacturing of engineered hypoimmunogenic cellular compositions, and uses thereof.

The present disclosure relates to improved cell compositions and potency assays for obtaining same, which may be suitable for use in connection with T-cell mediated diseases such as graft-versus-host disease (GvHD).

Nucleic acid molecules comprising truncated forms of the human cytomegalovirus (CMV) promoter are operably linked to a transgene of interest, including those encoding eNOS protein are taught. Vectors comprising these nucleic acid molecules and host cells transformed by these vectors and methods of producing cellular compositions are used for the treatment of a variety of pulmonary and cardiac diseases. There is provided a truncated human cytomegalovirus (CMV) enhancer element comprising SEQ ID NO: 1 or a functional derivative thereof. A truncated human cytomegalovirus (CMV) promoter comprising the truncated CMV enhancer element is taught. A polynucleotide expression cassette comprising the truncated CMV promoter and a transcribable polynucleotide operably linked to the truncated CMV promoter polynucleotide construct, a host cell comprising the polynucleotide expression cassette, and use of the host cell treat renal, vascular, pulmonary, or cardiac disease in the patient are taught.